Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah) is for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.

Daver says that he believes the success seen in this setting with CAR T-cell therapy will spread to adult and older populations, as well.